[421]
Pancreatic Cancer Genetics
[7,9 KB]
From [content.karger.com] Last viewed: 07.09.2006
[422]
Intraductal Spread of Pancreatic Cancer
[7,9 KB]
From [content.karger.com] Last viewed: 07.09.2006
[423]
Hereditary Pancreatic Cancer
[0,3 KB]
From [content.karger.com] Last viewed: 07.09.2006
[424]
Pancreatic Cancer: Does Octreotide Offer Any Promise?
[7,9 KB]
From [content.karger.com] Last viewed: 07.09.2006
[425]
Weekly Gemcitabine and 24-Hour Infusional 5-Fluorouracil in ...
[7,9 KB]
From [content.karger.com] Last viewed: 07.09.2006
[426]
Expression Profiles of a Human Pancreatic Cancer Cell Line upon ...
[7,9 KB]
From [content.karger.com] Last viewed: 07.09.2006
[427]
Gemcitabine: Progress in the Treatment of Pancreatic Cancer
[7,9 KB]
From [content.karger.com] Last viewed: 07.09.2006
[428]
Recent Discoveries in Cancer Genetics of Exocrine Pancreatic Neoplasia
[7,9 KB]
From [content.karger.com] Last viewed: 07.09.2006
[429]
Adrenomedullin antagonist suppresses in vivo growth of human ...
[214,8 KB]
From [eprints.lib.hokudai.ac.jp] Last viewed: 07.09.2006
[430]
Physical Activity, Obesity, Height, and the Risk of Pancreatic ...
[149,1 KB]
From [jama.ama-assn.org] Last viewed: 07.09.2006
[431]
INVITED REVIEW ARTICLE ONCOLOGICAL PROBLEMS IN PANCREATIC CANCER ...
[71,6 KB]
From [ir.nul.nagoya-u.ac.jp] Last viewed: 07.09.2006
[432]
Acinar-to-ductal metaplasia in pancreatic cancer development ...
[60,8 KB]
From [www.jci.org] Last viewed: 07.09.2006
[433]
CoVee, K- ras mutations and pancreatic cancer: A heterogeneous ...
[213,3 KB]
From [jech.bmjjournals.com] Last viewed: 07.09.2006
[434]
Debate CoVee, pancreatic cancer and the question of causation
[114,4 KB]
From [jech.bmjjournals.com] Last viewed: 07.09.2006
[435]
Pancreatic cancer. Management
From [wwwscielo.isciii.es] Last viewed: 07.09.2006
[436]
Adjuvant therapy for pancreatic cancer: current status and future ...
From [wwwscielo.isciii.es] Last viewed: 07.09.2006
[437]
Changes in chemotherapy for pancreatic cancer
From [sunzi1.lib.hku.hk] Last viewed: 07.09.2006
[438]
Epidemiology and diagnosis of the pancreatic cancer
From [wwwscielo.isciii.es] Last viewed: 07.09.2006
[439]
Pancreatic Cancer Snapshot.indd
[2296,1 KB]
From [planning.cancer.gov] Last viewed: 10.07.2006
[440]
Pancreatic Cancer: An Agenda for Action
[1143,1 KB]
From [planning.cancer.gov] Last viewed: 10.07.2006
[441]
Pancreatic Cancer Awareness Foundation Sarasota Walk – November 18 ...
[100,4 KB]
From [www.sarasotawalk.org] Last viewed: 06.07.2006
Pancreatic Cancer Awareness Foundation
Sarasota Walk – November 18, 2006
WALK SPONSOR FORM
Collected By: Name _
Address _Telephone __
•
To register your sponsored walk, email register@sarasotawalk.org
•
Please print the form and complete it in ink.
•
Please make checks payable to Pancreatic Cancer Awareness Foundation
or PCAF , PO Box 2111, Sarasota, FL 34230.
Thank you for all your help and enthusiasm.
Please submit your forms and checks no later than Monday, November 9
th
TOTAL COLLECTED $ ...
[442]
The Effectiveness of Gemcitabine for Pancreatic Cancer
[465,1 KB]
From [www.hta.ac.uk] Last viewed: 06.07.2006
Preoperative Ml&Staging
of Patients with Pancreatic Cancer
E. Castillo,MD, U. Fischer,MD, B. Salamat,MD, 0. Horstmann,MD*, E. Grabbe MD.
Departments of Radiology and General Surgery*, Georg-August-Universitit mingen, Germany
Purpose: to evaluate the role of a single MRI
evaluation for a complete preoperative
evaluation of patients with suspected pancreatic
cancer .
Material and Methods: 55 consecutive patients
(19 female, 36 male) with suspicion of
pancreatic malignancy were preoperatively
examined with MRI during a 1 l-month period.
All examinations were performed with a 1.5T
imager (Magnetom Vision; Siemens, Erlangen,
Germany) with use of a phased-array body coil.
Imaging consisted of the following pulse
sequences: 1) axial breath-hold Tl-weighted
gradient recalled-echo (fast low-angle shot,
FLASH) without fat suppression and T2-
weighted fat suppressed ...
[443]
Combined therapy of patients with pancreatic cancer complicated ...
[80,9 KB]
From [www.potopalsky.kiev.ua] Last viewed: 06.07.2006
pancreatic
cancer
1186
Combined therapy of patients with pancreatic cancer complicated with jaundice using amitozyn preparation
O.I.Dronov, Ya.M. Susak, E.A. Kryuchina
Bohomolets National Medical University, Kyiv, Ukraine
Kyiv Center for liver, biliary tracts and pancreas surgery, Kyiv, Ukraine.
Introduction
In the developed countries, pancreas cancer ranks fifth of all the tumors and second of digestive system tumors. Common disease incidence is 2 to 3 % of common oncological one, and the mortality rate is 4 to 5 %. Compared to other tumor localizations, the results on pancreatic cancer treatment are among the worst. Thus, half of the patients die in the period of 4 to 6 months after being diagnosed, and a five year survival is never more than 3%.[1].
The absence of early pathognomonic symptoms ...
[444]
AUSTCANCER COMMENCES PHASE II CLINICAL STUDY OF RP101 FOR ...
[115,7 KB]
From [austcancer.com.au] Last viewed: 06.07.2006
Contact:
Paul Hopper
Rob Whetstone/Rosemary Moothart
Managing Director
Investor Relations
Australian Cancer Technology
PondelWilkinson Inc.
Phone: +61 2 9252 6899
Phone: (310) 279-5980 (U.S.)
Mob: +61 407 118 366
Email: paulhopper@austcancer.com.au
AUSTCANCER COMMENCES PHASE II CLINICAL STUDY
OF RP101 FOR METASTATIC PANCREATIC CANCER
Sydney, Australia – December 14, 2004 – Australian Cancer Technology (“AustCancer” –
ASX:ACU), today said it has initiated a Phase II clinical study of RP101 for the treatment of
metastatic pancreatic cancer .
The eight-month study, which will include 22 patients with metastatic pancreatic cancer , will
be conducted at three leading centers in Germany: Chemnitz Clinics in collaboration with the
Technical University Dresden; Munich University of Technology’s Kilinikum rechts der Isar;
and, University of Munich Hospital’s ...
[445]
AUSTCANCER COMMENCES PHASE II CLINICAL STUDY OF RP101 FOR ...
[115,7 KB]
From [www.avantogen.com] Last viewed: 06.07.2006
Contact:
Paul Hopper
Rob Whetstone/Rosemary Moothart
Managing Director
Investor Relations
Australian Cancer Technology
PondelWilkinson Inc.
Phone: +61 2 9252 6899
Phone: (310) 279-5980 (U.S.)
Mob: +61 407 118 366
Email: paulhopper@austcancer.com.au
AUSTCANCER COMMENCES PHASE II CLINICAL STUDY
OF RP101 FOR METASTATIC PANCREATIC CANCER
Sydney, Australia – December 14, 2004 – Australian Cancer Technology (“AustCancer” –
ASX:ACU), today said it has initiated a Phase II clinical study of RP101 for the treatment of
metastatic pancreatic cancer .
The eight-month study, which will include 22 patients with metastatic pancreatic cancer , will
be conducted at three leading centers in Germany: Chemnitz Clinics in collaboration with the
Technical University Dresden; Munich University of Technology’s Kilinikum rechts der Isar;
and, University of Munich Hospital’s ...
[446]
N Veggies Tied to Lower Pancreatic Cancer Risk ST
[126,3 KB]
From [irandaily.ir] Last viewed: 06.07.2006
N
ew research from Canada suggests that a diet rich in
fruits and vegetables may help prevent pancreatic
cancer , a particularly deadly type of tumor, Reuters
said.
The findings, based on a comparison of 585 pancreatic
cancer patients and about 4,779 adults without the disease,
suggest that the risk of the cancer declines as fruit and veg-
etable intake increases.
Among cancers, pancreatic tumors have one of the most
dismal survival rates, with less than 5 percent of patients still
alive 5 years after diagnosis. The poor prognosis is in large
part due to the fact that the disease is rarely caught early.
Because of this, uncovering the modifiable risk factors for
the disease is vital, according to Dr. Parviz Ghadirian of the
University of Montreal, one of the authors of the new study.
Using data from a large study of Canadians diagnosed
with cancer between 1994 and 1997, Ghadirian ...
[447]
Phase III Study of PANVAC™-VF for Stage IV Pancreatic Cancer Phase ...
[107,8 KB]
From [therion.com] Last viewed: 06.07.2006
Phase III Study of PANVAC™-VF
for Stage IV Pancreatic Cancer
Title:
A Phase III Randomized,Controlled Study to Evaluate the Safety and Efficacy of PANVAC-VF in Combination
with GM-CSF Versus Best Supportive Care or Palliative Chemotherapy in Patients with Metastatic (Stage IV)
Adenocarcinoma of the Pancreas Who Have Failed a Gemcitibine-Containing Chemotherapy Regimen
Primary Endpoint:
Overall survival (OS),a logrank test will be performed to compare OS in the vaccine arm in combination
with GM-CSF versus best supportive care or palliative chemotherapy (investigator’s choice) in patients with
metastatic adenocarcinoma of the pancreas.
Secondary Endpoints:
1.Quality of life parameters;
2.Change in serum CEA and CA19-9 levels;
3.Response rate;
4.Safety.
PANVAC™-VF:
PANVAC-VF is an investigational cancer vaccine. The vaccine was developed based on the theory that a T-
...
[448]
Molecular mechanisms of PTHrPs growth regulation of pancreatic cancer
[10,3 KB]
From [www.cancer.ucsd.edu] Last viewed: 06.07.2006
P.I.: Michael Bouvet, M.D.
Title: Molecular Mechanisms of PTHrP’s Growth Regulation of Pancreatic
Cancer
PTHrP is an oncoprotein that regulates the growth and differentiation in virtually every
cell and tissue studied. We have recently demonstrated that PTHrP is commonly
expressed by pancreatic adenocarcinomas, the fourth leading cause of adult cancer
deaths in the US, and in preliminary studies that PTHrP regulates tumor growth. The
biological effects of PTHrP are both endocrine and intracrine, the former mediated
through a cell-surface receptor and the latter through a nuclear localizing sequence
(NLS). It is our Hypothesis that PTHrP mediates its growth regulatory effects in
pancreatic cancer through both cell-surface receptor and nuclear localization intracrine
mechanisms. Our goals are to elucidate these mechanisms by molecular biology studies
and to identify the growth-influencing ...
[449]
Establishment and Characterization of a Novel Human Pancreatic ...
[7,9 KB]
From [content.karger.com] Last viewed: 06.07.2006
A Novel Gene Transfer Therapy Against
Pancreatic Cancer (TNFerade) Delivered by
Endoscopic Ultrasound (EUS) and Percutaneous
Guided Fine Needle Injection (FNI)
Kenneth Chang, Nader Hanna, Stephen Swisher, Theodore Chung,
J. Randolph Hecht, Stephen Vogel, Alexander Rosemurgy, John
Nemunaitis, John Gibbs, Tony Reid, Jennifer Macko, Paul Kessler,
Mitchell Posner, James Farrell, Shane Grundy, Harlan Pinto,
Roy Soetikno, Irving Waxman, Neil Senzer
A Novel Gene Transfer Therapy Against
A Novel Gene Transfer Therapy Against
Pancreatic Cancer (
Pancreatic Cancer ( TNFerade
TNFerade ) Delivered by
) Delivered by
Endoscopic
Endoscopic Ultrasound (EUS) and
Ultrasound (EUS) and Percutaneous
Percutaneous
Guided Fine Needle Injection (FNI)
Guided Fine Needle Injection (FNI)
Kenneth Chang,
Kenneth ...
[450]
Tolfenamic Acid and Pancreatic Cancer Growth, Angiogenesis, and Sp ...
From [jncicancerspectrum.oxfordjournals.org] Last viewed: 06.07.2006
ORIGINAL PAPER
Meta-analysis of microarray data on pancreatic cancer defines a set
of commonly dysregulated genes
Robert Grützmann
1,6
Hinnerk Boriss
2,6
, Ole Ammerpohl
3
, Jutta Lüttges
4
, Holger Kalthoff
3
,
Hans Konrad Schackert
5
, Günter Klöppel
4
, Hans Detlev Saeger
1
and Christian Pilarsky*
,1
1
Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Technical University of Dresden,
Dresden, Germany;
2
Interdisciplinary Center for Bioinformatics, Leipzig, Germany;
3
Department of Molecular Oncology, Clinic for
General Surgery and Thoracic Surgery, University of Kiel, Germany;
4
Department of Pathology, University of Kiel, Germany;
...
Found 1450 documents
Page 15 of 49 Pages:
<< < 10 11 12 13 14 15 16 17 18 19 20 > >>
cancers
homepage
last week